Mr. Chair, I'll respond to the first question, and then ask the member to clarify the second question.
As I stated in my opening remarks, when we first identified the opportunity to bring a vaccine to market, we did work collaboratively with the Canadian government. We issued a five-point letter outlining what Pfizer's commitment was to pursue multiple levels of response to this pandemic.
Part of the challenge that we had, if we're comparing to other countries, is that the rolling submission process was not in place until September. Therefore, when we finalized our initial contract with the government in August, we anticipated a timeline that very much looked like Australia.
Australia received approval through its normal regulatory review process in late January, and initiated its first vaccinations of Pfizer's vaccine in that country in early February. It wasn't until mid-November that we identified a pathway that would allow us to bring this product to Canadians in December. Ever since then, we have been working to accelerate delivery to this country.